Skip to main content

OVID

Stock
Health Care
Biotechnology

Performance overview

OVID Price
Price Chart

Forward-looking statistics

Beta
1.46
Risk
85.23%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.

Company info

SectorHealth Care
IndustryBiotechnology
Employees47
Market cap$210.0M

Fundamentals

Enterprise value-$5.1M
Revenue$548.0K
Revenue per employee
Profit margin0.00%
Debt to equity24.34

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.34
Dividend per share
Revenue per share$0.01
Avg trading volume (30 day)$488K
Avg trading volume (10 day)$760K
Put-call ratio

Macro factor sensitivity

Growth-2.2
Credit+10.3
Liquidity+1.0
Inflation-6.0
Commodities-1.2
Interest Rates-1.8

Valuation

Dividend yield0.00%
PEG Ratio-0.87
Price to sales43.91
P/E Ratio-0.87
Enterprise Value to Revenue-9.32
Price to book0.41

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.

Zacks Investment Research (May 13, 2025)
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?

Monday, Takeda Pharmaceutical Co Ltd TAK announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).

Benzinga (June 17, 2024)
Texas abortion pill decision 'threatens the health of America,' Ovid Therapeutics CEO says

Ovid Therapeutics CEO Jeremy Levin joins Yahoo Finance Live's Anjalee Khemlani to discuss a Texas judge's ruling on an abortion pill ban, drugmakers opposing the decision, uncertainty for pharmaceutical development, and the outlook for the FDA.

Yahoo Finance (April 12, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free